2020-11-17
2022-10-17
2023-10-17
123
NCT04595058
Hospital Universitari de Bellvitge
Hospital Universitari de Bellvitge
INTERVENTIONAL
LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent
The aim of the study is to evaluate technical, clinical and safety outcomes of lumen-apposing metal stent (LAMS) with and without a coaxial double-pigtail plastic stent (DPS) in EUS-guided choledochoduodenostomies (CDS) for the management of biliary obstruction.
The introduction of specific biliary lumen-apposing metal stents (LAMS) represented a great technical improvement in EUS-guided transmural Biliary drainage (BD) of distal malignant biliary obstruction Data is still limited, but recent studies and reviews have been reported with acceptable technical and clinical success. However, some concerns exist regarding its safety, as secondary adverse events There are doubts concerning the possible benefits derived from the insertion of double-pigtail plastic stents (DPS) within the lumen-apposing metal stents (LAMS) in the EUS-guided choledochoduodenostomy (CDS). Our hypothesis is that adding a coaxial plastic stent may offer benefits in terms of safety in CDS.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates | Results Reporting Dates | Study Record Updates |
---|---|---|
2020-09-22 | N/A | 2024-04-16 |
2020-10-14 | N/A | 2024-04-18 |
2020-10-20 | N/A | 2022-12 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
Treatment
Allocation:
Randomized
Interventional Model:
Parallel
Masking:
None
Arms and Interventions
Participant Group/Arm | Intervention/Treatment |
---|---|
ACTIVE_COMPARATOR: EUSDB-LAMS Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stent . Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer. EUSDB-LAMS (Endoscopic ultrasound guided biliary drainage with lum | DEVICE: Double pigtail plastic stent through lumen-apposing metal stent
DEVICE: Lumen-apposing metal stent without double pigtail plastic stent
|
EXPERIMENTAL: EUSDB-LAMS-Pigtail Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stents without coaxial plastic stent. Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer. In this arm, a double pigtail throug | DEVICE: Double pigtail plastic stent through lumen-apposing metal stent
|
Primary Outcome Measures | Measure Description | Time Frame |
---|---|---|
Safety (Adverse events) | Safety will be measured by careful and comparative evaluation of adverse effects in both groups. | 12 months |
Recurrent biliary obstruction (RBO) | Recurrent biliary obstruction (RBO) has been defined as a composite endpoint of either occlusion or migration. | 12 months |
Secondary Outcome Measures | Measure Description | Time Frame |
---|---|---|
Clinical success | Resolution of jaundice or drop in total bilirubin level by > 50% within 2 weeks after the EUS-CD. | 2 weeks |
Technical success | Technical success was defined as successful placement of the LAMS between the bile duct and the duodenal lumen, creating a transmural ostomy. To evaluate the correct position of the transmural stent, the deployment of the internal flap in the lumen of the bile duct must be verified by ultrasound vision and the internal flap by endoscopic vision. | 24 hours. |
Survival | Survival is defined as the time elapsed between biliary drainage and the end of follow-up, either due to death and cessation of follow-up. | 12 months |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.
The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.